Becton Dickinson EBIT 2010-2025 | BDX
Becton Dickinson annual and quarterly EBIT history from 2010 to 2025. EBIT can be defined as earnings before interest and taxes.
- Becton Dickinson EBIT for the quarter ending March 31, 2025 was $547M, a 25.48% decline year-over-year.
- Becton Dickinson EBIT for the twelve months ending March 31, 2025 was $2.227B, a 7.58% increase year-over-year.
- Becton Dickinson 2024 annual EBIT was $2.398B, a 13.6% increase from 2023.
- Becton Dickinson 2023 annual EBIT was $2.111B, a 7.53% decline from 2022.
- Becton Dickinson 2022 annual EBIT was $2.283B, a 1.42% increase from 2021.
Becton Dickinson Annual EBIT
(Millions of US $) |
| 2024 |
$2,398 |
| 2023 |
$2,111 |
| 2022 |
$2,283 |
| 2021 |
$2,251 |
| 2020 |
$912 |
| 2019 |
$1,760 |
| 2018 |
$1,509 |
| 2017 |
$1,522 |
| 2016 |
$1,430 |
| 2015 |
$1,074 |
| 2014 |
$1,606 |
| 2013 |
$1,255 |
| 2012 |
$1,558 |
| 2011 |
$1,665 |
| 2010 |
$1,582 |
| 2009 |
$1,590 |
Becton Dickinson Quarterly EBIT
(Millions of US $) |
| 2025-03-31 |
$547 |
| 2024-12-31 |
$454 |
| 2024-09-30 |
$624 |
| 2024-06-30 |
$602 |
| 2024-03-31 |
$734 |
| 2023-12-31 |
$438 |
| 2023-09-30 |
$351 |
| 2023-06-30 |
$547 |
| 2023-03-31 |
$627 |
| 2022-12-31 |
$586 |
| 2022-09-30 |
$489 |
| 2022-06-30 |
$537 |
| 2022-03-31 |
$566 |
| 2021-12-31 |
$691 |
| 2021-09-30 |
$84 |
| 2021-06-30 |
$492 |
| 2021-03-31 |
$433 |
| 2020-12-31 |
$1,242 |
| 2020-09-30 |
$-317 |
| 2020-06-30 |
$359 |
| 2020-03-31 |
$369 |
| 2019-12-31 |
$501 |
| 2019-09-30 |
$112 |
| 2019-06-30 |
$626 |
| 2019-03-31 |
$136 |
| 2018-12-31 |
$886 |
| 2018-09-30 |
$576 |
| 2018-06-30 |
$511 |
| 2018-03-31 |
$187 |
| 2017-12-31 |
$235 |
| 2017-09-30 |
$491 |
| 2017-06-30 |
$-224 |
| 2017-03-31 |
$445 |
| 2016-12-31 |
$810 |
| 2016-09-30 |
$97 |
| 2016-06-30 |
$516 |
| 2016-03-31 |
$465 |
| 2015-12-31 |
$352 |
| 2015-09-30 |
$295 |
| 2015-06-30 |
$137 |
| 2015-03-31 |
$293 |
| 2014-12-31 |
$349 |
| 2014-09-30 |
$401 |
| 2014-06-30 |
$446 |
| 2014-03-31 |
$381 |
| 2013-12-31 |
$378 |
| 2013-09-30 |
$77 |
| 2013-06-30 |
$405 |
| 2013-03-31 |
$381 |
| 2012-12-31 |
$392 |
| 2012-09-30 |
$389 |
| 2012-06-30 |
$449 |
| 2012-03-31 |
$383 |
| 2011-12-31 |
$337 |
| 2011-09-30 |
$364 |
| 2011-06-30 |
$447 |
| 2011-03-31 |
$440 |
| 2010-12-31 |
$413 |
| 2010-09-30 |
$316 |
| 2010-06-30 |
$423 |
| 2010-03-31 |
$414 |
| 2009-12-31 |
$430 |
| 2009-09-30 |
$379 |
| 2009-06-30 |
$432 |
| 2009-03-31 |
$361 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$51.105B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
